abacavir
Antiinfectives for systemic use (J05)US regulatory status: approved.
pharma · Inflammatory Bowel Disease (IBD) · Melanoma · IRON
Disc Medicine
Disc Medicine drug portfolio — 200 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
321 Arsenal St., Suite 101, Watertown, Massachusetts 02472-5710, US HQ
165 Employees
Public company Type
IRON · NYSE Ticker
Company details
- Status
- Public
- HQ
- 321 Arsenal St., Suite 101, Watertown, Massachusetts 02472-5710, US
- Employees
- 165
- Programs
- 3
- Drugs
- 357
- Patents
- 6
Disc Medicine pipeline
Portfolio lens on 200 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Disc Medicine drug portfolio — 200 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: Human immunodeficiency virus type 1 reverse transcriptase.
- Target
- Human immunodeficiency virus type 1 reverse transcriptase
- Mechanism
- Human immunodeficiency virus type 1 reverse transcriptase inhibitor
-
US regulatory status: approved.
-
US regulatory status: approved. Molecular target: Synaptosomal-associated protein 25.
- Target
- Synaptosomal-associated protein 25
- Mechanism
- Synaptosomal-associated protein 25 inhibitor
-
US regulatory status: approved. Molecular target: Fatty-acid amide hydrolase 1.
- Target
- Fatty-acid amide hydrolase 1
- Mechanism
- Cyclooxygenase inhibitor
-
adalimumab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Tumor necrosis factor.
- Target
- Tumor necrosis factor
- Mechanism
- TNF-alpha inhibitor
-
agomelatine
Nervous system (N06)Nervous system (N06) compound in Disc Medicine's portfolio. Molecular target: Melatonin receptor.
- Target
- Melatonin receptor
- Mechanism
- Melatonin receptor agonist
-
US regulatory status: approved. Molecular target: Interleukin-2 receptor.
- Target
- Interleukin-2 receptor
- Mechanism
- Interleukin-2 receptor agonist
-
alectinib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Disc Medicine's portfolio. Mechanism: EML4-ALK.
- Mechanism
- EML4-ALK
-
alglucosidase alfa
Alimentary tract and metabolism (A16)US regulatory status: approved. Molecular target: Starch.
- Target
- Starch
- Mechanism
- Starch hydrolytic enzyme
-
alitretinoin
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Retinoid receptor.
- Target
- Retinoid receptor
- Mechanism
- Retinoid receptor agonist
-
US regulatory status: approved. Molecular target: Tissue-type plasminogen activator.
- Target
- Tissue-type plasminogen activator
- Mechanism
- Tissue-type plasminogen activator exogenous protein
-
US regulatory status: approved. Molecular target: Dopamine receptors; D2 & D3.
- Target
- Dopamine receptors; D2 & D3
- Mechanism
- Serotonin (5-HT) receptor antagonist
-
Development asset linked to Disc Medicine in public FDA and regional records. Mechanism: Serotonin transporter inhibitor.
- Mechanism
- Serotonin transporter inhibitor
-
US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.
- Target
- Bacterial penicillin-binding protein
- Mechanism
- Bacterial penicillin-binding protein inhibitor
-
US regulatory status: approved. Molecular target: Ergosterol.
- Target
- Ergosterol
- Mechanism
- Ergosterol sequestering agent
-
anakinra
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Interleukin-1 receptor type 1.
- Target
- Interleukin-1 receptor type 1
- Mechanism
- Interleukin-1 receptor antagonist
-
US regulatory status: approved. Molecular target: Type-1 angiotensin II receptor.
- Target
- Type-1 angiotensin II receptor
- Mechanism
- Type-1 angiotensin II receptor agonist
-
anifrolumab
Antineoplastic and immunomodulating agents (L04)Antineoplastic and immunomodulating agents (L04) compound in Disc Medicine's portfolio. Molecular target: Interferon alpha/beta receptor 1.
- Target
- Interferon alpha/beta receptor 1
- Mechanism
- Interferon-alpha/beta receptor alpha chain antagonist
-
anti-melanoma mab fragments
Various (V09)Various (V09) compound in Disc Medicine's portfolio. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
apalutamide
Antineoplastic and immunomodulating agents (L02)US regulatory status: approved. Molecular target: Androgen receptor.
- Target
- Androgen receptor
- Mechanism
- Androgen Receptor antagonist
-
aripiprazole
Nervous system (N05)US regulatory status: approved. Molecular target: D(2) dopamine receptor.
- Target
- D(2) dopamine receptor
- Mechanism
- Serotonin 2a (5-HT2a) receptor antagonist
-
asenapine
Nervous system (N05)US regulatory status: approved. Mechanism: Serotonin 2a (5-HT2a) receptor antagonist.
- Mechanism
- Serotonin 2a (5-HT2a) receptor antagonist
-
atazanavir sulfate
Antiinfectives for systemic use (J05)US regulatory status: approved. Molecular target: Human immunodeficiency virus type 1 protease.
- Target
- Human immunodeficiency virus type 1 protease
- Mechanism
- Human immunodeficiency virus type 1 protease inhibitor
-
atezolizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.
- Target
- Programmed cell death 1 ligand 1
- Mechanism
- Programmed cell death 1 ligand 1 inhibitor
-
Development asset linked to Disc Medicine in public FDA and regional records. Mechanism: Norepinephrine transporter inhibitor.
- Mechanism
- Norepinephrine transporter inhibitor
-
Development asset linked to Disc Medicine in public FDA and regional records. Mechanism: HMG-CoA reductase inhibitor.
- Mechanism
- HMG-CoA reductase inhibitor
-
atropine
Sensory organs (S01)US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M1.
- Target
- Muscarinic acetylcholine receptor M1
- Mechanism
- Muscarinic acetylcholine receptor M1 antagonist
-
atropine sulfate
Sensory organs (S01)US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M1.
- Target
- Muscarinic acetylcholine receptor M1
- Mechanism
- Muscarinic acetylcholine receptor M3 antagonist
-
autologous glioma tumor cell lysates (inactivated)
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Disc Medicine's portfolio.
-
avalglucosidase alfa
Alimentary tract and metabolism (A16)Alimentary tract and metabolism (A16) compound in Disc Medicine's portfolio. Molecular target: Glycogen.
- Target
- Glycogen
- Mechanism
- Glycogen hydrolytic enzyme
-
avelumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.
- Target
- Programmed cell death 1 ligand 1
- Mechanism
- Programmed cell death 1 ligand 1 other
-
axicabtagene ciloleucel
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Disc Medicine's portfolio. Molecular target: B-lymphocyte antigen CD19.
- Target
- B-lymphocyte antigen CD19
- Mechanism
- B-lymphocyte antigen CD19 binding agent
-
azathioprine
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Amidophosphoribosyltransferase.
- Target
- Amidophosphoribosyltransferase
- Mechanism
- Amidophosphoribosyltransferase inhibitor
-
US regulatory status: approved. Molecular target: Bacterial 70S ribosome.
- Target
- Bacterial 70S ribosome
- Mechanism
- Bacterial 70S ribosome inhibitor
-
Development asset linked to Disc Medicine in public FDA and regional records. Molecular target: Polymerase acidic protein.
- Target
- Polymerase acidic protein
- Mechanism
- Polymerase acidic protein inhibitor
-
US regulatory status: approved. Molecular target: Polymerase acidic protein.
- Target
- Polymerase acidic protein
- Mechanism
- Polymerase acidic protein inhibitor
-
baricitinib
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Tyrosine-protein kinase JAK1.
- Target
- Tyrosine-protein kinase JAK1
- Mechanism
- Tyrosine-protein kinase JAK2 inhibitor
-
basiliximab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Interleukin-2 receptor.
- Target
- Interleukin-2 receptor
- Mechanism
- Interleukin-2 receptor inhibitor
-
beclometasone
Respiratory system (R03)Respiratory system (R03) compound in Disc Medicine's portfolio.
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
bevacizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Vascular endothelial growth factor A, long form.
- Target
- Vascular endothelial growth factor A, long form
- Mechanism
- Vascular endothelial growth factor A inhibitor
-
binimetinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Dual specificity mitogen-activated protein kinase kinase 1.
- Target
- Dual specificity mitogen-activated protein kinase kinase 1
- Mechanism
- Dual specificity mitogen-activated protein kinase kinase 1 inhibitor
-
bortezomib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: 26S proteasome.
- Target
- 26S proteasome
- Mechanism
- 26S proteosome inhibitor
-
bosutinib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Disc Medicine's portfolio. Molecular target: Tyrosine-protein kinase ABL1.
- Target
- Tyrosine-protein kinase ABL1
- Mechanism
- Tyrosine-protein kinase ABL inhibitor
-
botulinum toxin type a
Musculo-skeletal system (M03)Musculo-skeletal system (M03) compound in Disc Medicine's portfolio. Molecular target: Synaptosomal-associated protein 25.
- Target
- Synaptosomal-associated protein 25
- Mechanism
- Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme
-
brexpiprazole
Nervous system (N05)US regulatory status: approved. Molecular target: D(2) dopamine receptor.
- Target
- D(2) dopamine receptor
- Mechanism
- Serotonin 2a (5-HT2a) receptor antagonist
-
budesonide
Alimentary tract and metabolism (A07)US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
buprenorphine
Nervous system (N07)US regulatory status: approved. Molecular target: Kappa-type opioid receptor.
- Target
- Kappa-type opioid receptor
- Mechanism
- Kappa opioid receptor agonist
-
US regulatory status: approved. Molecular target: Kappa-type opioid receptor.
- Target
- Kappa-type opioid receptor
- Mechanism
- Mu opioid receptor agonist
-
Development asset linked to Disc Medicine in public FDA and regional records. Mechanism: Dopamine transporter inhibitor.
- Mechanism
- Dopamine transporter inhibitor
-
c1 inhibitor (human)
Blood and blood forming organs (B06)Blood and blood forming organs (B06) compound in Disc Medicine's portfolio. Molecular target: Coagulation factor XI.
- Target
- Coagulation factor XI
- Mechanism
- Coagulation factor XI inhibitor
-
cabazitaxel
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
cabozantinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Mechanism: Hepatocyte growth factor receptor inhibitor.
- Mechanism
- Hepatocyte growth factor receptor inhibitor
-
US regulatory status: approved.
-
US regulatory status: approved. Mechanism: Dihydrofolate reductase inhibitor.
- Mechanism
- Dihydrofolate reductase inhibitor
-
canagliflozin
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Sodium/glucose cotransporter 2.
- Target
- Sodium/glucose cotransporter 2
- Mechanism
- Sodium/glucose cotransporter 2 inhibitor
-
cannabidiol
Nervous system (N03)US regulatory status: approved. Molecular target: Cannabinoid receptor 1.
- Target
- Cannabinoid receptor 1
- Mechanism
- Cannabinoid CB1 receptor negative allosteric modulator
-
capecitabine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- Thymidylate synthase inhibitor
-
capsaicin
Nervous system (N01)US regulatory status: approved. Molecular target: Transient receptor potential cation channel subfamily V member 1.
- Target
- Transient receptor potential cation channel subfamily V member 1
- Mechanism
- Vanilloid receptor opener
-
US regulatory status: approved. Molecular target: Sodium channel alpha subunit.
- Target
- Sodium channel alpha subunit
- Mechanism
- Sodium channel alpha subunit blocker
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
carfilzomib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: 26S proteasome.
- Target
- 26S proteasome
- Mechanism
- 26S proteosome inhibitor
-
cariprazine
Nervous system (N05)Nervous system (N05) compound in Disc Medicine's portfolio. Mechanism: Dopamine D3 receptor modulator.
- Mechanism
- Dopamine D3 receptor modulator
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.
- Target
- Bacterial penicillin-binding protein
- Mechanism
- Bacterial penicillin-binding protein inhibitor
-
US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.
- Target
- Bacterial penicillin-binding protein
- Mechanism
- Bacterial penicillin-binding protein inhibitor
-
cemiplimab
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Disc Medicine's portfolio. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
-
certolizumab pegol
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Tumor necrosis factor.
- Target
- Tumor necrosis factor
- Mechanism
- TNF-alpha inhibitor
-
cetuximab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Epidermal growth factor receptor.
- Target
- Epidermal growth factor receptor
- Mechanism
- Epidermal growth factor receptor erbB1 inhibitor
-
US regulatory status: approved. Molecular target: D2-like dopamine receptor.
- Target
- D2-like dopamine receptor
- Mechanism
- D2-like dopamine receptor antagonist
-
US regulatory status: approved. Molecular target: Polypeptides.
- Target
- Polypeptides
- Mechanism
- Polypeptides proteolytic enzyme
-
ciclosporin
Sensory organs (S01)Sensory organs (S01) compound in Disc Medicine's portfolio. Molecular target: Peptidyl-prolyl cis-trans isomerase A.
- Target
- Peptidyl-prolyl cis-trans isomerase A
- Mechanism
- Cyclophilin A modulator
-
cipaglucosidase alfa
Alimentary tract and metabolism (A16)Alimentary tract and metabolism (A16) compound in Disc Medicine's portfolio. Molecular target: Glycogen.
- Target
- Glycogen
- Mechanism
- Glycogen hydrolytic enzyme
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
Development asset linked to Disc Medicine in public FDA and regional records. Mechanism: Serotonin transporter inhibitor.
- Mechanism
- Serotonin transporter inhibitor
-
US regulatory status: approved. Molecular target: Bacterial 70S ribosome.
- Target
- Bacterial 70S ribosome
- Mechanism
- Bacterial 70S ribosome inhibitor
-
US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.
- Target
- GABA-A receptor; anion channel
- Mechanism
- GABA-A receptor; anion channel positive allosteric modulator
-
Development asset linked to Disc Medicine in public FDA and regional records. Mechanism: Serotonin transporter inhibitor.
- Mechanism
- Serotonin transporter inhibitor
-
clopidogrel
Blood and blood forming organs (B01)Blood and blood forming organs (B01) compound in Disc Medicine's portfolio. Mechanism: Purinergic receptor P2Y12 antagonist.
- Mechanism
- Purinergic receptor P2Y12 antagonist
-
US regulatory status: approved. Molecular target: P2Y purinoceptor 12.
- Target
- P2Y purinoceptor 12
- Mechanism
- Purinergic receptor P2Y12 antagonist
-
Development asset linked to Disc Medicine in public FDA and regional records.
-
US regulatory status: approved. Molecular target: D(2) dopamine receptor.
- Target
- D(2) dopamine receptor
- Mechanism
- Serotonin 2a (5-HT2a) receptor antagonist
-
cobicistat
Various (V03)US regulatory status: approved. Molecular target: Cytochrome P450 3A.
- Target
- Cytochrome P450 3A
- Mechanism
- Cytochrome P450 3A inhibitor
-
colchicine
Musculo-skeletal system (M04)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
US regulatory status: approved.
-
US regulatory status: approved. Molecular target: Adrenocorticotropic hormone receptor.
- Target
- Adrenocorticotropic hormone receptor
- Mechanism
- Melanocortin receptor 2 agonist
-
Development asset linked to Disc Medicine in public FDA and regional records.
-
crizotinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: ALK tyrosine kinase receptor.
- Target
- ALK tyrosine kinase receptor
- Mechanism
- Hepatocyte growth factor receptor inhibitor
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
dabrafenib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Disc Medicine's portfolio. Mechanism: Serine/threonine-protein kinase B-raf inhibitor.
- Mechanism
- Serine/threonine-protein kinase B-raf inhibitor
-
dapagliflozin
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Sodium/glucose cotransporter 2.
- Target
- Sodium/glucose cotransporter 2
- Mechanism
- Sodium/glucose cotransporter 2 inhibitor
-
daratumumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1.
- Target
- ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1
- Mechanism
- Lymphocyte differentiation antigen CD38 inhibitor
-
darbepoetin alfa
Blood and blood forming organs (B03)US regulatory status: approved. Molecular target: Erythropoietin receptor.
- Target
- Erythropoietin receptor
- Mechanism
- Erythropoietin receptor agonist
-
darolutamide
Antineoplastic and immunomodulating agents (L02)US regulatory status: approved. Molecular target: Androgen receptor.
- Target
- Androgen receptor
- Mechanism
- Androgen Receptor antagonist
-
dasatinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Bcr/Abl fusion protein.
- Target
- Bcr/Abl fusion protein
- Mechanism
- SRC inhibitor
-
Development asset linked to Disc Medicine in public FDA and regional records.
-
denosumab
Musculo-skeletal system (M05)US regulatory status: approved. Molecular target: Tumor necrosis factor ligand superfamily member 11.
- Target
- Tumor necrosis factor ligand superfamily member 11
- Mechanism
- Tumor necrosis factor ligand superfamily member 11 inhibitor
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
US regulatory status: approved. Molecular target: Sodium-dependent noradrenaline transporter.
- Target
- Sodium-dependent noradrenaline transporter
- Mechanism
- Norepinephrine transporter inhibitor
-
US regulatory status: approved. Molecular target: Sodium-dependent noradrenaline transporter.
- Target
- Sodium-dependent noradrenaline transporter
- Mechanism
- Norepinephrine transporter inhibitor
-
US regulatory status: approved. Molecular target: Sodium-dependent noradrenaline transporter.
- Target
- Sodium-dependent noradrenaline transporter
- Mechanism
- Serotonin transporter inhibitor
-
dexamethasone phosphate
Systemic hormonal preparations (H02)Systemic hormonal preparations (H02) compound in Disc Medicine's portfolio.
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
US regulatory status: approved. Molecular target: Sodium-dependent dopamine transporter.
- Target
- Sodium-dependent dopamine transporter
- Mechanism
- Norepinephrine transporter inhibitor
-
US regulatory status: approved. Molecular target: Sodium/potassium-transporting ATPase.
- Target
- Sodium/potassium-transporting ATPase
- Mechanism
- Sodium/potassium-transporting ATPase inhibitor
-
Development asset linked to Disc Medicine in public FDA and regional records. Mechanism: Voltage-gated L-type calcium channel blocker.
- Mechanism
- Voltage-gated L-type calcium channel blocker
-
US regulatory status: approved. Molecular target: 3',5'-cyclic phosphodiesterase.
- Target
- 3',5'-cyclic phosphodiesterase
- Mechanism
- 3',5'-cyclic phosphodiesterase inhibitor
-
docetaxel
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
dolutegravir
Antiinfectives for systemic use (J05)US regulatory status: approved.
-
doravirine
Antiinfectives for systemic use (J05)US regulatory status: approved. Molecular target: Human immunodeficiency virus type 1 reverse transcriptase.
- Target
- Human immunodeficiency virus type 1 reverse transcriptase
- Mechanism
- Human immunodeficiency virus type 1 reverse transcriptase negative allosteric modulator
-
Development asset linked to Disc Medicine in public FDA and regional records. Molecular target: Sodium-dependent noradrenaline transporter.
- Target
- Sodium-dependent noradrenaline transporter
- Mechanism
- Norepinephrine transporter inhibitor
-
US regulatory status: approved. Molecular target: Cannabinoid receptor 1.
- Target
- Cannabinoid receptor 1
- Mechanism
- Cannabinoid CB1 receptor agonist
-
duloxetine
Nervous system (N06)Nervous system (N06) compound in Disc Medicine's portfolio. Mechanism: Serotonin transporter inhibitor.
- Mechanism
- Serotonin transporter inhibitor
-
US regulatory status: approved. Molecular target: Sodium-dependent noradrenaline transporter.
- Target
- Sodium-dependent noradrenaline transporter
- Mechanism
- Norepinephrine transporter inhibitor
-
durvalumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.
- Target
- Programmed cell death 1 ligand 1
- Mechanism
- Programmed cell death 1 ligand 1 inhibitor
-
edoxaban
Blood and blood forming organs (B01)US regulatory status: approved. Mechanism: Coagulation factor X inhibitor.
- Mechanism
- Coagulation factor X inhibitor
-
elotuzumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: SLAM family member 7.
- Target
- SLAM family member 7
- Mechanism
- SLAM family member 7 inhibitor
-
emicizumab
Blood and blood forming organs (B02)US regulatory status: approved. Molecular target: Coagulation factor IX and X.
- Target
- Coagulation factor IX and X
- Mechanism
- Coagulation factor IX and X other
-
empagliflozin
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Sodium/glucose cotransporter 2.
- Target
- Sodium/glucose cotransporter 2
- Mechanism
- Sodium/glucose cotransporter 2 inhibitor
-
emtricitabine
Antiinfectives for systemic use (J05)US regulatory status: approved. Molecular target: Human immunodeficiency virus type 1 reverse transcriptase.
- Target
- Human immunodeficiency virus type 1 reverse transcriptase
- Mechanism
- Human immunodeficiency virus type 1 reverse transcriptase inhibitor
-
Development asset linked to Disc Medicine in public FDA and regional records.
-
encorafenib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Serine/threonine-protein kinase B-raf.
- Target
- Serine/threonine-protein kinase B-raf
- Mechanism
- Serine/threonine-protein kinase B-raf inhibitor
-
enfortumab vedotin
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Disc Medicine's portfolio. Molecular target: Nectin-4.
- Target
- Nectin-4
- Mechanism
- Tubulin inhibitor
-
enoxaparin sodium
Blood and blood forming organs (B01)US regulatory status: approved. Molecular target: Antithrombin-III.
- Target
- Antithrombin-III
- Mechanism
- Antithrombin-III activator
-
enzalutamide
Antineoplastic and immunomodulating agents (L02)US regulatory status: approved. Molecular target: Androgen receptor.
- Target
- Androgen receptor
- Mechanism
- Androgen Receptor antagonist
-
epinephrine
Cardiovascular system (C01)US regulatory status: approved. Molecular target: Adrenergic receptor.
- Target
- Adrenergic receptor
- Mechanism
- Adrenergic receptor agonist
-
US regulatory status: approved. Molecular target: Bacterial 70S ribosome.
- Target
- Bacterial 70S ribosome
- Mechanism
- Bacterial 70S ribosome inhibitor
-
Development asset linked to Disc Medicine in public FDA and regional records. Mechanism: Serotonin transporter inhibitor.
- Mechanism
- Serotonin transporter inhibitor
-
US regulatory status: approved. Molecular target: Sodium-dependent serotonin transporter.
- Target
- Sodium-dependent serotonin transporter
- Mechanism
- Serotonin transporter inhibitor
-
esketamine
Nervous system (N06)Nervous system (N06) compound in Disc Medicine's portfolio. Molecular target: Glutamate [NMDA] receptor.
- Target
- Glutamate [NMDA] receptor
- Mechanism
- Glutamate [NMDA] receptor negative allosteric modulator
-
Development asset linked to Disc Medicine in public FDA and regional records. Mechanism: Beta-1 adrenergic receptor antagonist.
- Mechanism
- Beta-1 adrenergic receptor antagonist
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
-
etanercept
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Tumor necrosis factor.
- Target
- Tumor necrosis factor
- Mechanism
- TNF-alpha inhibitor
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
-
US regulatory status: approved. Molecular target: ATP.
- Target
- ATP
- Mechanism
- ATP inhibitor
-
US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.
- Target
- GABA-A receptor; anion channel
- Mechanism
- GABA-A receptor; anion channel positive modulator
-
etravirine
Antiinfectives for systemic use (J05)US regulatory status: approved. Molecular target: Human immunodeficiency virus type 1 reverse transcriptase.
- Target
- Human immunodeficiency virus type 1 reverse transcriptase
- Mechanism
- Human immunodeficiency virus type 1 reverse transcriptase inhibitor
-
everolimus
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Peptidyl-prolyl cis-trans isomerase FKBP1A.
- Target
- Peptidyl-prolyl cis-trans isomerase FKBP1A
- Mechanism
- FK506-binding protein 1A inhibitor
-
exenatide
Alimentary tract and metabolism (A10)Alimentary tract and metabolism (A10) compound in Disc Medicine's portfolio. Molecular target: Glucagon-like peptide 1 receptor.
- Target
- Glucagon-like peptide 1 receptor
- Mechanism
- Glucagon-like peptide 1 receptor agonist
-
fentanyl
Nervous system (N02)US regulatory status: approved. Molecular target: Mu-type opioid receptor.
- Target
- Mu-type opioid receptor
- Mechanism
- Mu opioid receptor agonist
-
US regulatory status: approved. Molecular target: Mu-type opioid receptor.
- Target
- Mu-type opioid receptor
- Mechanism
- Mu opioid receptor agonist
-
US regulatory status: approved. Mechanism: Supplement.
- Mechanism
- Supplement
-
US regulatory status: approved.
-
filgotinib
Antineoplastic and immunomodulating agents (L04)Antineoplastic and immunomodulating agents (L04) compound in Disc Medicine's portfolio. Molecular target: Tyrosine-protein kinase JAK1.
- Target
- Tyrosine-protein kinase JAK1
- Mechanism
- Tyrosine-protein kinase JAK3 inhibitor
-
Development asset linked to Disc Medicine in public FDA and regional records. Molecular target: Tyrosine-protein kinase JAK1.
- Target
- Tyrosine-protein kinase JAK1
- Mechanism
- Tyrosine-protein kinase JAK2 inhibitor
-
finerenone
Cardiovascular system (C09)US regulatory status: approved. Molecular target: Mineralocorticoid receptor.
- Target
- Mineralocorticoid receptor
- Mechanism
- Mineralocorticoid receptor antagonist
-
florbetaben (18f)
Various (V09)Various (V09) compound in Disc Medicine's portfolio. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
US regulatory status: approved. Molecular target: Lanosterol 14-alpha demethylase.
- Target
- Lanosterol 14-alpha demethylase
- Mechanism
- Cytochrome P450 51 inhibitor
-
US regulatory status: approved. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- Thymidylate synthase inhibitor
-
US regulatory status: approved. Molecular target: Sodium-dependent serotonin transporter.
- Target
- Sodium-dependent serotonin transporter
- Mechanism
- Serotonin transporter inhibitor
-
US regulatory status: approved. Molecular target: D(2) dopamine receptor.
- Target
- D(2) dopamine receptor
- Mechanism
- Dopamine D2 receptor antagonist
-
Development asset linked to Disc Medicine in public FDA and regional records.
-
Development asset linked to Disc Medicine in public FDA and regional records. Mechanism: Serotonin transporter inhibitor.
- Mechanism
- Serotonin transporter inhibitor
-
US regulatory status: approved. Molecular target: Sodium-dependent serotonin transporter.
- Target
- Sodium-dependent serotonin transporter
- Mechanism
- Serotonin transporter inhibitor
-
folic acid
Various (V04)US regulatory status: approved.
-
fosamprenavir
Antiinfectives for systemic use (J05)Antiinfectives for systemic use (J05) compound in Disc Medicine's portfolio.
-
US regulatory status: approved. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
gallium (68ga) chloride
Various (V09)Various (V09) compound in Disc Medicine's portfolio.
-
US regulatory status: approved. Mechanism: Diagnostic.
- Mechanism
- Diagnostic
-
US regulatory status: approved. Mechanism: Diagnostic.
- Mechanism
- Diagnostic
-
US regulatory status: approved. Mechanism: DNA polymerase (alpha/delta/epsilon) inhibitor.
- Mechanism
- DNA polymerase (alpha/delta/epsilon) inhibitor
-
US regulatory status: approved. Molecular target: Peroxisome proliferator-activated receptor alpha.
- Target
- Peroxisome proliferator-activated receptor alpha
- Mechanism
- Peroxisome proliferator-activated receptor alpha agonist
-
US regulatory status: approved. Molecular target: Glucagon receptor.
- Target
- Glucagon receptor
- Mechanism
- Glucagon receptor agonist
-
golimumab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Tumor necrosis factor.
- Target
- Tumor necrosis factor
- Mechanism
- TNF-alpha inhibitor
-
gozetotide
Various (V09)Various (V09) compound in Disc Medicine's portfolio. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
US regulatory status: approved. Molecular target: D2-like dopamine receptor.
- Target
- D2-like dopamine receptor
- Mechanism
- Serotonin 2a (5-HT2a) receptor antagonist
-
Development asset linked to Disc Medicine in public FDA and regional records. Molecular target: Antithrombin-III.
- Target
- Antithrombin-III
- Mechanism
- Antithrombin-III activator
-
US regulatory status: approved. Molecular target: Enoyl-[acyl-carrier-protein] reductase [NADH] FabI.
- Target
- Enoyl-[acyl-carrier-protein] reductase [NADH] FabI
- Mechanism
- Bacterial enoyl-[acyl-carrier-protein] reductase inhibitor
-
US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M1.
- Target
- Muscarinic acetylcholine receptor M1
- Mechanism
- Muscarinic acetylcholine receptor M1 antagonist
-
human normal immunoglobulin
Antiinfectives for systemic use (J06)Antiinfectives for systemic use (J06) compound in Disc Medicine's portfolio. Mechanism: Replacement therapy, immunomodulatory effects.
- Mechanism
- Replacement therapy, immunomodulatory effects
-
human normal immunoglobulin (ivig)
Antiinfectives for systemic use (J06)Antiinfectives for systemic use (J06) compound in Disc Medicine's portfolio. Mechanism: Replacement therapy, immunomodulatory effects.
- Mechanism
- Replacement therapy, immunomodulatory effects
-
human normal immunoglobulin (scig)
Antiinfectives for systemic use (J06)Antiinfectives for systemic use (J06) compound in Disc Medicine's portfolio. Mechanism: Replacement therapy, immunomodulatory effects.
- Mechanism
- Replacement therapy, immunomodulatory effects
-
human papillomavirus 9-valent vaccine (recombinant, adsorbed)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Disc Medicine's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
human papillomavirus vaccine [types 6, 11, 16, 18] (recombinant, adsorbed)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Disc Medicine's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
hydrocortisone
Systemic hormonal preparations (H02)US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
Development asset linked to Disc Medicine in public FDA and regional records. Mechanism: Mu opioid receptor agonist.
- Mechanism
- Mu opioid receptor agonist
-
Development asset linked to Disc Medicine in public FDA and regional records. Mechanism: Toll-like receptor 7 antagonist.
- Mechanism
- Toll-like receptor 7 antagonist
-
US regulatory status: approved. Molecular target: Ferriprotoporphyrin IX.
- Target
- Ferriprotoporphyrin IX
- Mechanism
- Toll-like receptor 9 antagonist
-
US regulatory status: approved.
-
imatinib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Disc Medicine's portfolio. Mechanism: Tyrosine-protein kinase ABL inhibitor.
- Mechanism
- Tyrosine-protein kinase ABL inhibitor
-
Development asset linked to Disc Medicine in public FDA and regional records. Mechanism: Serotonin transporter inhibitor.
- Mechanism
- Serotonin transporter inhibitor
-
US regulatory status: approved. Molecular target: Sodium-dependent noradrenaline transporter.
- Target
- Sodium-dependent noradrenaline transporter
- Mechanism
- Serotonin transporter inhibitor
-
imlifidase
Antineoplastic and immunomodulating agents (L04)Antineoplastic and immunomodulating agents (L04) compound in Disc Medicine's portfolio. Molecular target: Antibodies.
- Target
- Antibodies
- Mechanism
- Antibodies hydrolytic enzyme
-
US regulatory status: approved.
-
infliximab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Tumor necrosis factor.
- Target
- Tumor necrosis factor
- Mechanism
- TNF-alpha inhibitor
-
influenza vaccine (h1n1)v (split virion, inactivated, adjuvanted)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Disc Medicine's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
influenza vaccine (live attenuated, nasal)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Disc Medicine's portfolio.
-
insulin human (rdna)
Alimentary tract and metabolism (A10)Alimentary tract and metabolism (A10) compound in Disc Medicine's portfolio. Molecular target: Insulin receptor.
- Target
- Insulin receptor
- Mechanism
- Insulin receptor agonist
-
interferon alfa-2a
Antineoplastic and immunomodulating agents (L03)Antineoplastic and immunomodulating agents (L03) compound in Disc Medicine's portfolio. Molecular target: Interferon alpha/beta receptor.
- Target
- Interferon alpha/beta receptor
- Mechanism
- Interferon alpha/beta receptor agonist
-
ioflupane (123i)
Various (V09)Various (V09) compound in Disc Medicine's portfolio. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
US regulatory status: approved. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
ipilimumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Cytotoxic T-lymphocyte protein 4.
- Target
- Cytotoxic T-lymphocyte protein 4
- Mechanism
- Cytotoxic T-lymphocyte protein 4 inhibitor
-
Development asset linked to Disc Medicine in public FDA and regional records. Mechanism: DNA topoisomerase I inhibitor.
- Mechanism
- DNA topoisomerase I inhibitor
-
US regulatory status: approved. Molecular target: DNA topoisomerase 1.
- Target
- DNA topoisomerase 1
- Mechanism
- DNA topoisomerase I inhibitor
-
irinotecan hydrochloride trihydrate
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Disc Medicine's portfolio. Molecular target: DNA topoisomerase 1.
- Target
- DNA topoisomerase 1
- Mechanism
- DNA topoisomerase I inhibitor
-
Development asset linked to Disc Medicine in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Supplement.
- Mechanism
- Supplement